Physician profile
Matthew Lemer
NPI 1598717589
$9,576.04
in general payments reported to CMS, 2019-2025
37 companies · $2,310 in 2025
The $2,310 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $431 · 2021: $1,420 · 2022: $1,115 · 2023: $1,722 · 2024: $1,535 · 2025: $2,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,566.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $1,196.89 | 2019-2024 | Xiaflex, Aveed, Edex |
| Teleflex LLC | $1,115.37 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $1,022.51 | 2019-2024 | Myrbetriq, Xtandi |
| Pfizer INC. | $658.94 | 2019-2025 | |
| Endo USA, INC. | $547.41 | 2024-2025 | Xiaflex, Aveed, Edex |
| Abbvie INC. | $510.36 | 2019-2025 | |
| Antares Pharma, INC. | $474.89 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Immunitybio, INC. | $389.79 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $383.91 | 2019-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $367.60 | 2022-2025 | |
| Janssen Biotech, INC. | $355.54 | 2019-2025 | Erleada, Balversa, Akeega |
| Allergan, INC. | $340.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $310.04 | 2020-2025 | Lynparza, Keytruda |
| Urogen Pharma, INC. | $299.16 | 2025 | |
| Tolmar, INC. | $189.25 | 2024-2025 | Jatenzo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $180.15 | 2021-2024 | Prolaris, Myrisk |
| Dendreon Pharmaceuticals LLC | $164.74 | 2020-2025 | Provenge |
| Myovant Sciences INC. | $121.65 | 2022 | |
| Progenics Pharmaceuticals, INC. | $89.31 | 2021-2025 | |
| Coloplast Corp | $89.28 | 2019-2025 | |
| 180 Medical, INC. | $78.25 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $77.62 | 2021-2022 | |
| Dentsply Ih Ab | $74.48 | 2024-2025 | Lofric |
| Sumitomo Pharma America, INC. | $70.34 | 2023 | Orgovyx |
| Amgen INC. | $61.85 | 2022-2023 | Xgeva |
| Urovant Sciences INC | $54.44 | 2021-2022 | |
| Olympus America INC. | $50.74 | 2024-2025 | Itind System |
| Hollister Incorporated | $46.25 | 2020-2022 | |
| Accord Healthcare, INC. | $45.88 | 2023-2024 | |
| Blue Earth Diagnostics | $40.52 | 2021-2023 | |
| Halozyme INC | $36.10 | 2023 | |
| Aytu Biopharma, INC. | $31.21 | 2019-2020 | |
| Dentsply Ih INC. | $27.99 | 2019 | |
| Verity Pharmaceuticals INC. | $21.93 | 2024 | Trelstar |
| Axonics, INC. | $19.64 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $15.83 | 2019 | |
| Boston Scientific Corporation | $15.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.